Lenalidomide Sandoz 15 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 15 Mg Hard Capsules, is an immunomodulatory agent presented as a 15 mg hard capsule for oral use. It is indicated for the treatment of certain blood cancers such as multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sandoz 15 Mg Hard Capsules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

- Multiple myeloma: reduces tumor burden and prolongs progression‑free survival. - Myelodysplastic syndromes with del(5q): improves blood counts and reduces transfusion dependence. - Mantle cell lymphoma: contributes to disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Diarrhea: loose stools occurring intermittently. - Constipation: difficulty passing stools. - Nausea: sensation of urge to vomit. - Rash: mild skin redness or itching. - Low blood counts (e.g., neutropenia): reduced white blood cells increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia or leukopenia: markedly low white blood cell counts. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Peripheral neuropathy: nerve damage causing tingling or numbness.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor appropriately. - Pregnancy risk: drug is contraindicated in pregnancy due to teratogenic potential; ensure effective contraception. - Thromboembolic risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: adjust use in patients with severe renal dysfunction. - Drug interactions: avoid concomitant use with strong CYP inducers without supervision. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of thrombosis when combined without prophylaxis. - Immunosuppressants (e.g., cyclosporine): may enhance immunosuppression. - Live vaccines: risk of infection; avoid concurrent administration.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may modestly increase plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): could affect clearance. - Hormonal contraceptives: may have reduced efficacy; advise additional contraception.